This content is machine translated Acute leukemia: Disease management Priorities from the perspective of patients and family caregivers Studies launched by the patient organization ALAN (The Acute Leukemia Advocates Network) map patient preferences in acute leukemia on the one hand and record the situation of relatives involved in...…
View Post 4 min This content is machine translated Current findings on myelofibrosis Reduce anemia and transfusion dependency Myelofibrosis (MF) is a rare clonal disease of pluripotent hematopoietic stem and progenitor cells. There have been significant advances in the treatment options for MF in recent years, but anemia...…
View Post 4 min This content is machine translated Case series Bleeding prophylaxis for von Willebrand disease Von Willebrand’s disease is predominantly inherited in an autosomal dominant manner and is the most common hereditary cause of a bleeding tendency. It is caused by a quantitative and/or qualitative...…
View Post 6 min This content is machine translated EHA 2025 Progress in multiple myeloma The annual meeting of the European Hematology Association (EHA) has been one of the most important focal points for international haematology for many years. With more than 15,000 participants on...…
View Post 8 min This content is machine translated Hematology The goal in sight: Optimal outcomes for hematology patients In hematology, the annual meeting of the European Hematology Association is one of the dates in the annual schedule. The association promotes excellence in patient care, research and education in…
View Post 3 min This content is machine translated Breast Cancer New options in advanced breast cancer While new lecture formats had to be established due to the Corona pandemic, substantial progress in research around cancer therapies remained constant, as evidenced by study results presented at EHA.…
View Post 3 min This content is machine translated Hematologic neoplasms New findings change the standards of diagnostics and therapy There is a lot happening in the landscape of hematologic neoplasms. This year, several potentially standard-changing studies could be presented to Congress at . Fitting to the claim of the annual…
View Post 4 min This content is machine translated EHA in Stockholm CAR-T cells – New therapeutic approach for multiple myeloma There are new therapeutic approaches in multiple myeloma. For example, the efficacy and safety of CAR-T cells are being studied. In particular, they could be applicable in the refractory and…
View Post 5 min This content is machine translated EHA Congress in Copenhagen New therapeutic options and improved survival in acute leukemias This year, the congress of the European Hematology Association (EHA) was held in Copenhagen from June 9-12. We report encouraging study results on the therapy of AML in elderly patients…
View Post 3 min This content is machine translated Chronic myeloid leukemia When is it possible to stop therapy? Most patients with CML are dependent on therapy with a tyrosine kinase inhibitor for the rest of their lives. However, there is increasing research into when and in which patients…
View Post 4 min This content is machine translated EHA Congress in Vienna Multiple Myeloma News From June 11 to 14, 2015, the congress of the “European Hematology Association” took place in Vienna. Among many other news, there were of course also updates on multiple myeloma.…
